ALL CONTENT OUTSOURCED PHARMA

• Quantifying Single-Use Waste Produced During mAb Manufacture
• Symbiosis Expands Commercial Capabilities With Addition Of New Stability Chamber
• Digital Standardization: Accelerating Gene Therapy Tech Transfer With Confidence And Compliance
• NuTekBio Facilities Tour
• The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time
• ROIS CDMO Closes On The Acquisition Of US Injectable Manufacturing Facility
• Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected For cGMP Manufacturing
• Merck Completes Acquisition Of JSR Life Sciences' Chromatography Business, Expanding Protein A Capabilities And Downstream Portfolio
• From QM To QMM For AI-Assisted Pharmaceutical Manufacturing Operations
• Swiss Rockets Collaborates With Lonza To Advance Torqur's Oncology Drug Candidate Bimiralisib Into Late-Stage Clinical Development
• The Systems And Choreography Needed For Grade B ATMP Material Transfer
• Synthetic DNA As An Alternative For Scalable Viral Vector Production
• Phio Pharmaceuticals Announces Agreement With U.S. cGMP Manufacturing Source For Drug Product, PH-762
• Does Biotech Need More Government Funding — Or A New Business Model?
• ImmuneOncia Therapeutics And Lonza Collaborate To Manufacture Danburstotug, A PD-L1 Antibody Targeting Immuno-Oncology
• uBriGene And Cellinfinity BIO Announce Strategic Partnership To Advance In Vivo CAR-T Therapies
• Immobilized Enzymes Promise Alternative To Cyanogen Bromide's Toxicity
• Rethinking ATMP Assurance When Sterility Timelines, Reality Misalign
• Investing In Early-Stage Oncology With Yosemite's Dan McHugh
• Mammalian Cell Line Development
• WuXiHigh 2.0 Delivers A 180 mg/mL Formula
• Systematic Strategy To Reduce The Cost Of Goods Sold
• WuXia293Stable: Express What CHO Can't
• Tool Enzymes For Antibody-Drug Conjugate Development And Manufacturing
• Kindeva® Commemorates 70 Years Of The pMDI As Inventors Are Inducted Into The 'National Inventors Hall Of Fame'
• Lifecore Biomedical Signs Two New Agreements With Existing U.S. Biopharmaceutical Customer
• Neion Bio Emerges From Stealth With Multi-Product Biosimilar Partnership Leveraging Its Cutting-Edge Genetic Engineering Platform
• SHINE And C-Ray Therapeutics Establish Strategic Partnership For Exclusive Distribution Of Non-Carrier-Added Lu-177 In Mainland China
• Navigating GMP Biosafety Challenges In ATMP Manufacturing
• Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
• Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka
• Engineering The Next Wave Of CHO Performance
• Pace Life Sciences Capabilities Update March 2026: Analytical Services
• Solvias Capabilities Update March 2026: Analytical Services
• Catalent Capabilities Update March 2026: Analytical Services
• Minaris Advanced Therapies Capabilities Update March 2026: Cell & Gene Therapy
• Lonza Capabilities Update March 2026: Cell & Gene Therapy
• Landmark Bio Capabilities Update March 2026: Cell & Gene Therapy
• Comprehensive Cell Solutions Capabilities Update March 2026: Cell & Gene Therapy
• Recipharm Advanced Bio Capabilities Update March 2026: Analytical Services
• Minaris Advanced Testing Capabilities Update March 2026: Analytical Services
• Fuji Pharma And Gedeon Richter Conclude Agreement For Joint Development Projects In Women's Health
• Applied StemCell And Cellipont Bioservices Partner To Offer A Seamless Path For iPSC-Derived Cell Therapy Development
• Yatiri Bio Enters Exclusive Option To In-License Agreement With Oscotec For Denfivontinib In AML
• SK pharmteco And Prozomix Announce Strategic Collaboration To Enhance Biocatalysis Capabilities For Global Drug Manufacturing
• Stability Issues Unique To Liquid Injectables And How To Avoid Them
• Lentitek And ViroCell Announce Commercial Collaboration
• What If The U.S. Government Stopped Funding Biotech?
• Cytiva And Yoshindo Advance Domestic Biosimilar Manufacturing In Japan Through FlexFactory Collaboration
• Lifecore Biomedical Signs Commercial Site Transfer Agreement With Leading Medical Aesthetics Company
• Just – Evotec Biologics Enters Project Agreement With BARDA To Optimize Biomanufacturing Of Antibodies Against Ebola And Related Viruses
• Generative AI Can Write The Code, But Who Builds In The Quality?
• Overcoming Food Effects, Variability, Solubility For A Non-Opioid Analgesic With Lipid-Based Formulations
• Overcoming API Constraints And Tight Timelines With On-Demand Manufacturing
• Formulation Strategies For Enhancing Bioavailability Of Challenging bRo5 Molecules
• Leveraging Softgel To Extend Vinorelbine's Lifecycle, Improve Patient Convenience
• Biocapacitance Measurement: A PAT Tool For Biomass Measurement In An Upstream Process
• A Cell Line Development Platform Accelerating Timelines To Clinic
• Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
• Aseptic Filling Quality Through Continuous Improvement
• Scaling Regenerative Medicine Production With PolarityBio's Nikolai Sopko, MD, Ph.D.
• Aseptic Filling Quality Delivered
• Aseptic Filling Quality Through Assurance
• Aseptic Filling Quality With A Sense Of Pride
• Aseptic Filling Quality Built Piece By Piece
• Aseptic Filling Quality Through Precision
• This Is Where Quality Starts
• From Design To Delivery: Aseptic Filling Workcell
• Quality Through Innovation
• Eveliqure And Serum Institute Of India Announce Strategic Collaboration On The Development Of Anti-Diarrhoeal Vaccines
• February 2026 — CDMO Opportunities And Threats Report
• COGs And Biology, Two Endpoints Needlessly At Odds In Advanced Therapy
• UK's Decentralized Manufacturing Could Be A Revolution; Mind The Risk
• Asimov Launches RNA Edge, A Lab-In-The-Loop Platform For AI Optimization Of RNA Therapeutic Candidates
• The Long Road To U.S. Vaccine Manufacturing
• Pyramid Pharma Services Signs Commercial Agreement With A Top 3 Global Pharma Innovator To Support siRNA Injectable Therapy
• All The Ways Global Biopharma Still Grapples With Annex 1
• Globalization vs. Localization: Where To Outsource In A Changing World
• Choosing The Right Outsourcing Model (CRO vs. CDMO vs. FSP)
• Strategic CDMO Partnerships: From Vendor To Collaborative Partner
• Trinity Biotech Announces Collaboration With University At Buffalo To Commercialize Novel Biomarkers For Sjögren's Syndrome
• Abzena Recognized As A Market-Leading Antibody-Drug Conjugate CDMO In Frost & Sullivan Radar Report
• Integrated Quality, Regulatory, And Safety Services
• Taiwan Bio Partners With Terumo Blood And Cell Technologies To Advance Automated Treg Manufacturing On Quantum Flex
• Viral Vector Manufacturing (VVMF) Enters Into Licensing Agreement With OXB, Gaining Access To The OXB AAV And LV Viral Vector Platforms
• Celltrion Signs Supply Agreement With A Global Biopharma Worth Up To KRW 375.4 Billion, Reflecting Recognition Of Product Quality And Manufacturing Productivity, And Accelerating CDMO Growth
• Continuous Manufacturing For API Breakthroughs
• CEO Insights And Trends: The Future Of The Sterile Filling CDMO Industry
• Bioprocess Training And Education
• Continuous Flow — An Emerging Alternative
• Small Molecule API Production: Unveiling The Impact Of Fermentation
• Accelerated API Manufacturing: Combining All Process Development Stages
• Improvements In ADC Efficacy And Stability
• A Faster Path To Genomic Medicine Feasibility
• Cytovance Biologics Capabilities Update March 2026: Large Molecule
• Minimizing Drug Product Loss In Manufacturing
• FDA's 483 Playbook: What It Means For Pharma Outsourcing — And What It Doesn't Address
• Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables
• Circular Single-Stranded Cell-Free DNA For Next-Gen Gene Editing
• George Medicines Extends Global Commercialization Of GMRx2 Into Australia And New Zealand With Arrotex Licensing Agreement
• BD Announces $110 Million To Support U.S. Pharmaceutical Supply Chain For Biologic Drugs
• Sartorius Launches Next-Generation Platform To Boost Efficiency In Cell Therapy Production
• BD And Ypsomed Expand Partnership To Address Rapidly Growing Biologics Market
• Advising The Biotech C-Suite To Reconsider Quality
• Don't Let Formulation Failures Derail Drug Development
• The Jones Act Hurts U.S. Pharmaceutical Manufacturing
• In Vitro Transcription For mRNA Production
• 3PBIOVIAN And INC Partner To Expand Access To Oncology Treatments In Colombia Through Biosimilar Development
• Trends In Mid-Size Scale Up Strategies
• Patented Process For Intermediates Useful For Etrasimod Arginine
• Patented Process For Intermediates Useful For Deucravacitinib
• Where Contamination Control Really Breaks Down In Practice
• Trends In FDA FY 2025 Warning Letters
• ElevateBio Capabilities Update March 2026: Cell & Gene Therapy
• The BioSecure Act And Unfiltered Supply Chain Realities
• The One Quality Metric That Actually Matters
• Navigating Private Equity Ownership In The CDMO Space
• What Great CDMO Selection Looks Like In 2026
• The "Bad News" Stress Test: How CDMOs Handle Escalation
• My Journey at Asymchem
• R&D Excellence at Asymchem's UK Facility
• Accelerating Small Molecule Development With Cutting-Edge Technology
• Quick View Of Asymchem's New OEB5 Facility
• Asymchem's State-Of-The-Art HTE Platform
• Celularity Reiterates Strategic Commercialization Partnership With NEXGEL Focused On Building Biomaterials Franchise With Established Commercial Products and New 510(k) Pathway Product Opportunities
• SUS Interchangeability Assessment And Qualification Best Practices
• Trenchant BioSystems And Invetech Group Complete Strategic Alliance Formation To Develop Fully Automated CGT Manufacturing Solution
• Fujifilm Invests In VALANX Biotech To Strengthen ADC CDMO Capabilities
• Delivery Strategy For Next-Gen Cardiac Gene Therapies
• Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
• Quotient Sciences Capabilities Update March 2026: Small Molecule Drug Product
• Pfizer CentreOne Capabilities Update March 2026: Small Molecule Drug Product
• PCI Pharma Services Capabilities Update March 2026: Small Molecule Drug Product
• Mikart Capabilities Update March 2026: Small Molecule Drug Product
• Enhancing Drug Performance Through Lipid-Based Formulations For CNS Indication
• Asymchem Capabilities Update March 2026: Small Molecule Drug Product
• SK Pharmteco Capabilities Update March 2026: Small Molecule Drug Substance
• Novartis Capabilities Update March 2026: Small Molecule Drug Substance
• Asymchem's World-Class TIDES Hub: Scaling Innovations For The Future
• Asymchem's Green Commitment
• Merck Signs MoU With Cyto-Facto To Advance Cell And Gene Therapy Development And Manufacturing In APAC
• George Medicines Signs Exclusive Licensing Agreement With Ahngook Pharmaceutical To Commercialize GMRx2 In Korea
• Bavarian Nordic And Serum Institute Of India Expand Strategic Partnership With Chikungunya Vaccine Manufacturing Agreement
• Accelerating Technology Diffusion In Cell And Gene Therapy
• ROIS Capabilities Update March 2026: Fill/Finish
• Novartis Capabilities Update March 2026: Fill/Finish
• Pursuing Quality While Maintaining Process Control With Richard Moroney, Ph.D.
• medac CDMO Capabilities Update March 2026: Fill/Finish
• Jubilant HollisterStier Capabilities Update March 2026: Fill/Finish
• Argonaut Capabilities Update March 2026: Fill/Finish